MyFinsight
Home
Blog
About
Contact
Download
Download image
Sale of marketable
securities
$11,692,686
Proceeds from issuance of
common stock for cash
$3,096,250
Exercise of stock options
$41,165
Net cash provided by
investing activities
$8,897,470
Net cash provided by
financing activities
$2,854,791
Canceled cashflow
$2,795,216
Canceled cashflow
$282,624
Net increase
(decrease) in cash and cash...
$963,298
Canceled cashflow
$10,788,963
Purchase of marketable
securities
$2,679,147
Purchases of equipment
$116,069
Stock-based compensation
$3,325,626
Accounts payable
$839,525
Depreciation and
amortization
$209,985
Accrued expenses and
other current...
$195,281
Accounts receivable
-$172,900
Prepaid expenses and
other current assets
-$101,770
Payment of issuance
costs
$177,953
Payment of deferred
offering costs
$99,973
Repayment of financed
insurance premiums
$4,698
Net cash used in
operating activities
-$10,788,963
Canceled cashflow
$4,845,087
Net loss
-$14,241,975
Change in fair value of
warrant liabilities
$1,121,502
Dividend and interest
income
$270,573
Back
Back
Cash Flow
source: myfinsight.com
BioRestorative Therapies, Inc. (BRTX)
BioRestorative Therapies, Inc. (BRTX)